Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Ongoing cash burn • Significant dilution ELVN is well-capitalized and debt-free, but persistent losses, negative cash flow, dilution, and a premium valuation unsupported by revenue warrant caution.
Price Behavior
Key Price Behavior Insights: • Persistent downtrend • Oversold momentum • Critical support Support Level: $49.12 Resistance Level: $50.24, then $53.36–$54.43 ELVN remains in a bearish last-month trend, but oversold RSI near support at $49.12 may support a rebound if it clears $50.24; otherwise, a break below support signals further weakness.
Sentiment & News
Key News Insights: • BlackRock stake • Strong Phase 1 • Cash runway BlackRock's 7.16% stake, strong ELVN-001 Phase 1 data, and $895M cash runway bolster Enliven's clinical and financial outlook.
AI Summary
ELVN is a well-funded, high-expectation clinical execution story—not a financing-risk biotech—so investors should focus on whether ELVN-001's Phase 1 differentiation holds in pivotal CML trials, as its ~$4.2B enterprise value leaves limited room for disappointment despite runway into 2030.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |